IN2012DN01984A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01984A
IN2012DN01984A IN1984DEN2012A IN2012DN01984A IN 2012DN01984 A IN2012DN01984 A IN 2012DN01984A IN 1984DEN2012 A IN1984DEN2012 A IN 1984DEN2012A IN 2012DN01984 A IN2012DN01984 A IN 2012DN01984A
Authority
IN
India
Prior art keywords
tfpi
aptamers
bind
disorders
nostics
Prior art date
Application number
Other languages
English (en)
Inventor
G Schaub Robert
Mcginness Kathleen
Nelson Jennifer
Genga Ryan
Waters Emily
C Kurz Jeffrey
L Diener John
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Publication of IN2012DN01984A publication Critical patent/IN2012DN01984A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
IN1984DEN2012 2009-08-18 2010-08-17 IN2012DN01984A (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23493909P 2009-08-18 2009-08-18
US35337410P 2010-06-10 2010-06-10
US36636210P 2010-07-21 2010-07-21
US36776610P 2010-07-26 2010-07-26
PCT/US2010/045797 WO2011022427A1 (en) 2009-08-18 2010-08-17 Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics

Publications (1)

Publication Number Publication Date
IN2012DN01984A true IN2012DN01984A (de) 2015-07-24

Family

ID=43607310

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1984DEN2012 IN2012DN01984A (de) 2009-08-18 2010-08-17

Country Status (17)

Country Link
US (1) US8252913B2 (de)
EP (1) EP2467167B1 (de)
JP (1) JP2013502218A (de)
KR (1) KR20120061086A (de)
CN (1) CN102869385A (de)
AU (1) AU2010284329B2 (de)
BR (1) BR112012003806A2 (de)
CA (1) CA2770762A1 (de)
CO (1) CO6531414A2 (de)
ES (1) ES2655589T3 (de)
IL (1) IL218048A0 (de)
IN (1) IN2012DN01984A (de)
MX (1) MX2012002133A (de)
NZ (1) NZ598557A (de)
RU (1) RU2012110221A (de)
SG (1) SG178408A1 (de)
WO (1) WO2011022427A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070166741A1 (en) 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
EP2379600B2 (de) 2008-12-22 2020-10-14 Novo Nordisk A/S Antikörper gegen gewebefaktor-hemmer
JP6002691B2 (ja) * 2011-02-11 2016-10-05 バクスアルタ ゲーエムベーハー 組織因子経路阻害剤に対するアプタマーおよび出血障害治療薬としてのそれらの使用
JP6022556B2 (ja) * 2011-06-08 2016-11-09 ミエドジナロドウィ インスティタット バイオロジーモレキュラーネイ アイ コモルコウェイ 配列特異的な操作されたリボヌクレアーゼｈ、および、ｄｎａ−ｒｎａハイブリッド結合タンパク質の配列優先性を決定する方法
WO2013142153A2 (en) * 2012-03-22 2013-09-26 Baxter International Inc. Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
DE102012020496A1 (de) 2012-10-18 2014-04-24 Charité - Universitätsmedizin Berlin Biomarker zur Diagnostik und Behandlung von Neurofibromatose Typ 1
EP3036542B1 (de) * 2013-06-21 2021-02-17 Imigene Inc. Eine methode zur untersuchung einer von einer person erhaltenen blutprobe
US10457743B2 (en) 2013-07-19 2019-10-29 Novo Nordisk A/S Antibodies recognizing the N-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
US9695424B2 (en) * 2013-09-09 2017-07-04 Somalogic, Inc. PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders
CA2944909A1 (en) 2014-04-04 2015-10-08 Bloodworks Routine laboratory and point-of-care (poc) testing for hemostasis
IL256517B2 (en) * 2015-06-23 2024-06-01 Childrens Hospital Philadelphia Modified factor IX, and preparations, methods and uses for gene transfer to cells, organs and tissues
WO2017062536A2 (en) * 2015-10-06 2017-04-13 Kieu Hoang A method of manfacturing prothrombin complex concentrate from fraction iii and non-prothrombin complex concentrate from fraction iv
EP3385383B1 (de) * 2015-12-04 2021-04-07 Zenyaku Kogyo Co., Ltd. Anti-il-17-aptamer mit verbesserter retention im blut
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体
CN115792231B (zh) * 2022-11-04 2023-07-25 中拓生物有限公司 一种基于凝血酶适配体调节的酶级联反应的DNase I生物传感器

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5981471A (en) * 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
AU757175B2 (en) 1997-09-05 2003-02-06 Regents Of The University Of California, The Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
JP3313358B2 (ja) * 1998-11-09 2002-08-12 栄研化学株式会社 核酸の合成方法
US6514948B1 (en) 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
WO2003102212A2 (en) * 2002-05-31 2003-12-11 Regents Of The University Of Minnesota In vitro evaluation of nucleic acid ligands
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US20080161425A1 (en) * 2005-07-29 2008-07-03 Universiteit Van Maastricht Regulation of Tissue Factor Activity by Protein S and Tissue Factor Pathway Inhibitor

Also Published As

Publication number Publication date
CO6531414A2 (es) 2012-09-28
WO2011022427A1 (en) 2011-02-24
EP2467167B1 (de) 2017-08-16
ES2655589T3 (es) 2018-02-20
KR20120061086A (ko) 2012-06-12
NZ598557A (en) 2013-08-30
SG178408A1 (en) 2012-03-29
RU2012110221A (ru) 2013-09-27
US20110098345A1 (en) 2011-04-28
IL218048A0 (en) 2012-04-30
AU2010284329A1 (en) 2012-03-29
BR112012003806A2 (pt) 2016-11-16
US8252913B2 (en) 2012-08-28
EP2467167A4 (de) 2013-12-25
CN102869385A (zh) 2013-01-09
JP2013502218A (ja) 2013-01-24
AU2010284329B2 (en) 2015-04-16
MX2012002133A (es) 2013-02-15
CA2770762A1 (en) 2011-02-24
EP2467167A1 (de) 2012-06-27

Similar Documents

Publication Publication Date Title
IN2012DN01984A (de)
MX2012011771A (es) Aptameros para beta-ngf y su uso en el tratamiento de enfermedades y trastornos mediados por beta-ngf.
AU2018236800B2 (en) DNA-PK inhibitors
MX2021001169A (es) Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas.
WO2012174487A3 (en) Bromodomain inhibitors and uses thereof
WO2012151512A3 (en) Bromodomain inhibitors and uses thereof
WO2012088290A3 (en) Tri-variable domain binding proteins and uses thereof
WO2012075383A3 (en) Bromodomain inhibitors and uses thereof
WO2013151736A3 (en) In vivo production of proteins
MY169987A (en) Selective pi3k delta inhibitors
MX2016001394A (es) Anticuerpos anti-activina a y usos de los mismos.
PH12014501108A1 (en) Anti-il-36r antibodies
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2011060049A3 (en) Spiro-oxindole mdm2 antagonists
WO2012138487A3 (en) Oligonucleotide modulation of splicing
WO2014028493A3 (en) Exosomes and micro-ribonucleic acids for tissue regeneration
EP2590671A4 (de) Immunglobuline mit zweifacher variabler domäne und ihre verwendung
WO2012065022A3 (en) Spiro-oxindole mdm2 antagonists
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
PH12016501122A1 (en) Delayed release compositions of linaclotide
WO2010083207A3 (en) Protein kinase c inhibitors and uses thereof
MX2013012053A (es) Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos.
WO2011163478A3 (en) Dual variable domain immunoglobulins and uses thereof
WO2013055899A3 (en) Compositions useful in treating nephropathy and methods for preparation of same
WO2012125981A3 (en) Raf kinase inhibitors